Mankind grey market premium

Delhi-based Mankind Pharma is likely to debut on the bourses with a double-digit premium on May 9, said market observers. This is largely attributed to the strong demand seen from qualified institutional buyers (QIBs) to the initial public offering (IPO) and healthy market conditions. The IPO was subscribed 15.32 times during May 25-27, with QIBs applying for 49.16 times the allotted quota of shares. The portion set aside for high networth individuals (HNIs) was subscribed 3.8 times and the retail investor part was booked 92 percent. The IPO was entirely an offer for sale by promoters and investors. Hence the entire money has been received by selling shareholders, and the company did not get money from the share sale. "We expect the company to open 8-10 percent higher on listing day, as fundamentals of the company look good from a long-term perspective including the domestic focus of the business, strong distribution network and good products at affordable prices," said Prathamesh Masdekar, research analyst at Stoxbox. Profitable listing Astha Jain, a senior research analyst at Hem Securities, also expects Mankind Pharma to list at a 10 percent premium to the issue price of Rs 1,080 a share. Anubhuti Mishra, an equity research analyst at Swastika Investmart, too, anticipates a profitable listing, adding that the success of the IPO listing will ultimately depend on the overall market sentiment. The rising grey market premium in the last few days, especially after improved e...

• • • • Mankind Pharma is about to release its IPO on Apr 25, 2023. The issue is closing on Apr 27, 2023, and is currently having an active grey market. The Mankind Pharma IPO GMP is running at a stable rate as per the current situation. In IPO, the GMP or the Grey Market Premium is the premium amount at which the IPO shares are traded before getting listed in the stock market. However, the QIB and the HNI numbers are the key indicators of GMP in the case of Mankind Pharma IPO. The company is intended to raise Rs 4,326.36 Crore by the released issue. Mankind Pharma IPO GMP Rates, Kotak rates & SS This particular table represents everything related to the IPO event from its opening and closing date along with the face value of the issue. You can check this table related to know the IPO size, and price band listing details, and more. Date GMP (in INR) Kostak (in INR) Subject to Sauda (in INR) 05 May 2023 Rs 100 Rs 300 Rs 800 04 May 2023 Rs 80 Rs 300 Rs 800 03 May 2023 Rs 80 Rs 300 Rs 800 02 May 2023 Rs 80 Rs 300 Rs 800 28 Apr 2023 Rs 30 Rs 250 Rs 500 27 Apr 2023 Rs 40 Rs 500 Rs 750 26 Apr 2023 Rs 70 Rs 500 Rs 750 25 Apr 2023 Rs 70 Rs 500 Rs 750 24 Apr 2023 Rs 90 Rs 500 Rs 1000 23 Apr 2023 Rs 90 Rs 500 Rs 1000 22 Apr 2023 Rs 90 Rs 500 Rs 1000 21 Apr 2023 Rs 90 Rs 500 Rs 1000 20 Apr 2023 Rs 90 Rs 500 Rs 1000 19 Apr 2023 Rs 100 Rs 500 Rs 1000 18 Apr 2023 Rs 100 Rs 500 Rs 1000 17 Apr 2023 Rs 100 NA NA 14 Apr 2023 Rs 100 NA NA Check out Related IPO Links: Open Free Demat Account ...

Mankind Pharma Mankind Pharma develops and manufactures a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. Day 2: Mankind Pharma IPO Subscription Data (as of 05:00 PM Apr 26, 2023) QIB – 1.86x, NII – 1.02x - , Retail – 0.25x Total – 0.87x Mankind Pharma IPO Price The company has fixed Mankind Pharma IPO price band at Rs 1026 to Rs 1080 per equity share. Mankind Pharma IPO Offer Size The maiden public comprises only an offer for the sale of over 4 crore equity shares by promoters and investors, while there is no fresh issue portion. The total fundraising by the company would be Rs 4,110.03 at the lower price band, and Rs 4,326.35 crore at the higher band. Promoters Ramesh Juneja, Rajeev Juneja, and Sheetal Arora will be offloading over 1 crore shares via offer for sale, and the rest of the shares in the OFS will be sold by investors Cairnhill CIPEF, Cairnhill CGPE, Beige, and Link Investment Trust. Mankind Pharma IPO Objectives of Issue The main objectives of the offer would be to carry out the offer for sale by the selling shareholders and achieve the benefits of listing the equity shares on the stock exchanges. All the money raised via public issues will go to selling shareholders, and the company will not receive funds from the offer. Mankind Pharma IPO Financial The pharmaceutical company, which comes with a market capitalisation of Rs 43,264 crore, has reported a consolidat...

Mankind Pharma closed its maiden public issue on a strong note, getting subscribed over 15 times. Now all eyes will be on its share allotment which will be announced next week on May 3. The pharmaceutical company has received a robust response to its initial public offering from qualified institutional investors, who have bid 49.16 times the allotted quota, while high net-worth individuals have bought shares 3.8 times the reserved portion. However, the response from retail investors remained tepid, with only 92 percent of reserved shares subscribed. As a result, the offer has received bids for 42.95 crore equity shares subscribing 15.32 times during April 25-27. The company also received a good response in the anchor round with 16 MF schemes and names like CPPIB, Abu Dhabi Investment Authority, Goldman Sachs, Fidelity, Blackrock, GIS and Nomura participating. The Rs 4,326-crore public issue was entirely an offer for sale by promoters and investors. Hence all the money will go to the selling shareholders, and the company will not receive funds from this offer. The price band for the offer was Rs 1,026-1,080 per share and the final offer price is expected to be at the upper end of the price band. Investors in the Mankind Pharma IPO can check their share allotment status either on the BSE website or the portal of the IPO registrar, by following a few easy steps. In case of IPO registrar website, a) Select IPO "Mankind Pharma Limited" b) Select and accordingly enter either "Ap...

What ICICI Securities says ​“We assign SUBSCRIBE rating on the back of opportunities from its newer acquired products and its plan to backward integrate in its power brands, structural preference for domestic branded formulations among broader healthcare themes,” said a report by ICICI Securities. ​ ​Aditya Birla Money’s view ​ ​“We believe that MPL’s market leadership and brand recognition coupled with Management’s bet on the recent acquisition of Panacea Biotech’s formulations may provide a huge growth opportunity for the company. We have a SUBSCRIBE recommendation to this issue,” said a report by Aditya Birla Money. ​ ​Key risks to the company​ ​The company says that after India, its major markets are the US, Bangladesh, Sri Lanka and Nepal. Any developments in the pharma industry in these regions could impact on its business operations. Besides, it is exposed to government price controls which could negatively affect its operations. ​

Mankind Pharma shares managed to attract single-digit premium in the grey market on the day of price band announcement and ahead of the IPO launch. The expensive valuations and only offer for sale portion in the IPO may be reasons for low premium, experts said. The offer will open for subscription in the coming week on April 25 and the closing date would be April 27, 2023. The pharmaceutical company on April 19 has fixed price band for its IPO at Rs 1,026-1,080 per share. More than 4 crore shares public issue is completely an offer for sale by promoters and investors, which means the company will not get funds through this offer and the entire amount will go to selling shareholders. The public issue in total will fetch the company Rs 4,326.35 crore at higher end of price band. Currently its shares are traded with around 7-8 percent premium in the grey market, analysts said. The grey market is an unofficial trading platform for IPO shares and is generally used by investors to know about expected demand to the issue and listing price. "The current grey market premium of Mankind Pharma of about 7 percent is not encouraging, considering the size of the IPO at about Rs 4,300 crore," Manish Chowdhury, Head of Research at Stoxbox said. He expects the grey market premium to dilute further over the period due to expensive valuations, higher borrowings and no use of proceeds for business purposes. He believes that there are better opportunities in the pharmaceutical space available ...

Mankind Pharma IPO: next closure of subscription, bidders and marketplace observers are eagerly looking forward to announcement of percentage allotment date, which is perhaps on third Would possibly 2023. As according to the tentative time table of this Prega Information and Manforce maker corporate’s preliminary public providing (IPO), Mankind Pharma IPO allotment date is perhaps on third Would possibly 2023. Then again, those that have carried out for the IPO needn’t to transport from pillar to publish as they are able to test their software standing on-line by way of logging in on the BSE web site or at professional registrar’s web site. In the meantime, as Mankind Pharma IPO allotment date is speedy coming near, gray marketplace has long past bullish at the public factor because the Minor marketplace has been in uptrend for remaining six days. Consistent with marketplace observers, stocks of Mankind Pharma Ltd are to be had at a top class of ₹92 in gray marketplace nowadays. Mankind Pharma IPO GMP nowadays Marketplace observers stated that Mankind Pharma IPO gray marketplace top class (GMP) nowadays is ₹92, which is ₹7 upper from its the day prior to this’s GMP of ₹85 apiece. They stated that Mankind Pharma IPO GMP has risen from ₹60 to ₹92 in remaining 3 days, which is basically because of the fashion reversal on Dalal Side road. They stated that bullish sentiments at Indian inventory marketplace has modified gray marketplace sentiments in regard to Mankind Pharma IPO...

IPO Grey Market Price (IPO GMP Premium & Kostak Rate) IPO Grey Market is the over-the-counter market where deals are done in-person only among the trusted group of investors. The deals are usually facilitated by the broker in neighborhood. In this market, an investor could sell IPO share or IPO application before the company gets listed on the stock exchange. IPO Grey Market Premium (IPO GMP) is the premium at which the IPO shares are traded in the grey market. Kostak Rate is the rate at which you can sell the IPO application for a fixed price irrespective to you get IPO allotment or not. Note: This page is a discussion forum. The messages express the views of the author of the message. We do not actively monitor the contents of posted messages on this forum. We are not responsible for the contents of any messages posted. Do not vouch for or warrant the accuracy, completeness or usefulness of any message. IPO Grey Market Discussion

IPO Grey Market Price (IPO GMP Premium & Kostak Rate) IPO Grey Market is the over-the-counter market where deals are done in-person only among the trusted group of investors. The deals are usually facilitated by the broker in neighborhood. In this market, an investor could sell IPO share or IPO application before the company gets listed on the stock exchange. IPO Grey Market Premium (IPO GMP) is the premium at which the IPO shares are traded in the grey market. Kostak Rate is the rate at which you can sell the IPO application for a fixed price irrespective to you get IPO allotment or not. Note: This page is a discussion forum. The messages express the views of the author of the message. We do not actively monitor the contents of posted messages on this forum. We are not responsible for the contents of any messages posted. Do not vouch for or warrant the accuracy, completeness or usefulness of any message. IPO Grey Market Discussion

Mankind Pharma closed its maiden public issue on a strong note, getting subscribed over 15 times. Now all eyes will be on its share allotment which will be announced next week on May 3. The pharmaceutical company has received a robust response to its initial public offering from qualified institutional investors, who have bid 49.16 times the allotted quota, while high net-worth individuals have bought shares 3.8 times the reserved portion. However, the response from retail investors remained tepid, with only 92 percent of reserved shares subscribed. As a result, the offer has received bids for 42.95 crore equity shares subscribing 15.32 times during April 25-27. The company also received a good response in the anchor round with 16 MF schemes and names like CPPIB, Abu Dhabi Investment Authority, Goldman Sachs, Fidelity, Blackrock, GIS and Nomura participating. The Rs 4,326-crore public issue was entirely an offer for sale by promoters and investors. Hence all the money will go to the selling shareholders, and the company will not receive funds from this offer. The price band for the offer was Rs 1,026-1,080 per share and the final offer price is expected to be at the upper end of the price band. Investors in the Mankind Pharma IPO can check their share allotment status either on the BSE website or the portal of the IPO registrar, by following a few easy steps. In case of IPO registrar website, a) Select IPO "Mankind Pharma Limited" b) Select and accordingly enter either "Ap...